Jasper is a biotechnology company focused on targeting mast cells to treat chronic mast cell diseases.
Our mission is to make safer and more effective therapy possible for patients with chronic mast cell-driven diseases. We are bringing together a team of biotech veterans and leading academic institutions to achieve our vision of developing new therapies for mast cell diseases.
Briquilimab is a targeted anti-c-Kit monoclonal antibody designed to deplete mast cells for the treatment of chronic immunological and inflammatory diseases.
Jasper is evaluating briquilimab across multiple diseases and is currently conducting clinical studies in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU) and allergic asthma.
Jasper Therapeutics’ management team is composed of experienced biopharma industry veterans with extensive track records in drug development and commercialization.
With this leadership, we are well positioned to achieve our vision of delivering new therapies to treat serious, chronic diseases.